Recent Updates
Recently added Catalysts

LXR-623

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Aug 7, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00366522Study Evaluating LXR-623 in Healthy SubjectsPHASE1 COMPLETED -Aug 1, 2006Sep 1, 2006Aug 7, 20091 United States
NCT00385489Study Evaluating LXR-623 in Healthy Japanese AdultsPHASE1 COMPLETED -Aug 1, 2006Sep 1, 2006Aug 7, 20091 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and Tolerability
Safety
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
LXR-623DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range19 Years — 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion: * Healthy, men or women, aged 19-50 years Exlcusion: * Use of any investigational or prescription drug within 30 days before study start * Any clinically imprtant medical disease or abnormal laboratory test results

Countries:United StatesJapan
Unlock Eligibility Criteria